Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Implantica publishes Year-end Report, January - December 2023 (Q4) | ||||||
By: PR Newswire Association LLC. - 16 Feb 2024 | Back to overview list |
|||||
VADUZ, Liechtenstein, Feb. 16, 2024 /PRNewswire/ -- RefluxStop™ - Gaining speed, breaking boundaries and going global Significant events in the fourth quarter of 2023
Significant events after the end of the period
Fourth quarter financial summary
Full year financial summary
Telephone conference Implantica will hold a teleconference on 16 February 2024 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast: Dial-in: numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference https://conference.financialhearings.com/teleconference/?id=5002461 For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs Officer Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@fnca.se This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-16 08:00 CET. About Implantica Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information. The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-year-end-report-january--december-2023-q4-302063913.html |
||||||
|
||||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |